YUNNAN BAIYAO(SZ:000538)2025-05-19 09:34Group 1: Pharmaceutical Business Growth - The pharmaceutical segment aims for significant growth in 2024 by focusing on becoming the leading brand in pain management, enhancing product efficacy, and expanding its ecosystem [2] - Clinical research on core products like Yunnan Baiyao (powder) and capsules for diabetic foot and skeletal pain has shown steady progress, opening broader application scenarios [4] - Marketing strategies, including the successful promotion of the self-owned sports IP "Let's Go Play Ball," have improved brand youthfulness and product penetration [4] Group 2: Health Products Channel Development - The company maintains a comprehensive national sales team for health products, with Yunnan Baiyao toothpaste leading the market share in the oral care category [5] - Continuous optimization of the entire channel has strengthened traditional offline advantages while exploring new retail formats, enhancing market competitiveness [5] Group 3: Provincial Pharmaceutical Company Performance - In 2024, the Provincial Pharmaceutical Company achieved a main business revenue of CNY 24.607 billion, a year-on-year increase of 0.48% [6] - Non-pharmaceutical business areas like medical devices and special medical foods saw a sales growth of 14% [7] - The OTC segment experienced an 18% sales increase, while the new specialty pharmacy model grew by 29% [7] Group 4: Future Investment and Acquisition Plans - The company plans to optimize its industrial portfolio through both "internal" and "external" collaborative development, focusing on strategic mergers and partnerships to overcome growth bottlenecks [8]